<DOC>
	<DOC>NCT02951364</DOC>
	<brief_summary>The primary objective of this post-marketing surveillance study is to collect and assess data related to the safety and effectiveness of HarvoniÂ® (ledipasvir/sofosbuvir (LDV/SOF)) treatment regimen, per the approved Korea prescribing information for Harvoni, in routine clinical practice in Korea and to report the results to the Ministry of Food and Drug Safety (MFDS). Patients will be treated as part of routine practice at Korean healthcare centers by accredited physicians.</brief_summary>
	<brief_title>Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
	<criteria>Key Patients aged 18 years and older who are living in Korea Patients with chronic HCV infection eligible for treatment with Harvoni as indicated in the approved prescribing information for Harvoni Patients who have been informed of all pertinent aspects of the study and have voluntarily signed an informed consent form Key Patients treated with Harvoni outside of the approved prescribing information in Korea Patients who have a contraindication to Harvoni Patients who have a contraindication to ribavirin Pregnant or breastfeeding women Patients who have previously been administered Harvoni Patients participating in a concurrent HCV clinical trial Patients planning on leaving the country during the study period Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>observational</keyword>
</DOC>